Infant Bacterial Therapeutics
Nigel Titford currently serves as the Head of Business Development at Infant Bacterial Therapeutics AB since September 2025, while also holding the position of CEO at BioGaia Pharma since August 2017. Previously, Nigel Titford was the Head of Business Development and VP of Business Development at BioGaia AB from March 2022 to August 2025, and from November 2007 to August 2017, respectively. Additional roles at BioGaia AB included Head of Business Unit Adult Health and Regional Director for North America, focusing on Business Development and Licensing in Nutrition. Nigel Titford's educational background includes a MEA in Business Administration and Business Law from Lund University and a BA(Hons) in European Business Studies from De Montfort University.
This person is not in any teams
This person is not in any offices
Infant Bacterial Therapeutics
IBT is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.